Nautilus Biotechnology Q3 net loss widens 15% to $15.64 million

Bitget2026/10/27 10:03

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Nautilus Biotechnology’s third-quarter 2026 net loss widened 15% year over year to $15.64 million.
Revenue reached $234,000, while operating expenses rose 10% year over year to $16.95 million.
Cash, cash equivalents and investments totaled $114.3 million at September 30, 2026.
Following quarter-end, Nautilus joined the ARPA-H-funded SEEDS consortium, expecting up to $6 million to study Alzheimer’s disease and cancer proteoforms.
Management maintained planned instrument availability in mid-2027, with development advancing toward twenty proteoform assays through mid-2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nautilus Biotechnology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610270600PRIMZONEFULLFEED9853750) on October 27, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Nautilus Biotechnology Q3 net loss widens 15% to $15.64 million

You may also like

Crypto prices